kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human Latent Activin A / INHBA Protein, His tag, 100µg  

Recombinant Human Latent Activin A / INHBA Protein, His tag, 100µg

Recombinant Human Latent Activin A  / INHBA Protein (Ser 21 - Ser 426), expressed from human 293 cells (HEK293), predicted N-terminus: His (pro) & Gly311 (mature), His tag

recombinant, human, Activin A, INHBA

More details


Availability: within 7 days

533,00 €

Activin and inhibin are two closely related protein complexes that have almost directly opposite biological effects. Activin enhances FSH biosynthesis and secretion, and participates in the regulation of the menstrual cycle. Many other functions have been found to be exerted by activin, including roles in cell proliferation, differentiation, apoptosis, metabolism, homeostasis, immune response, wound repair, and endocrine function. Conversely inhibin down regulates FSH synthesis and inhibits FSH secretion.Activins are nonglycosylated homodimers or heterodimers of various β subunits (βA, βB, βC, and βE in mammals), while Inhibins are heterodimers of a unique α subunit and one of the β subunits. Activin A is a widely expressed homodimer of two βA chains. The βA subunit can also heterodimerize with a βB or βC subunit to form Activin AB and Activin AC, respectively. The 14 kDa mature human βA chain shares 100% amino acid sequence identity with bovine, feline, mouse, porcine, and rat βA.

Recombinant Human Latent Activin A, His Tag (ACA-H424x) is expressed from human 293 cells (HEK293). It contains AA Ser 21 - Ser 426 (Accession # AAH07858.1).
Predicted N-terminus: His (pro) & Gly311 (mature)

Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus
The protein has a calculated MW of 13.0 kDa (mature) and 32.0 kDa (pro). The protein migrates as 15 kDa (mature) and 43-48 kDa (pro) under reducing (R) condition, and 27 kDa (mature), 43-48 kDa (pro) and 60 kDa (pro & mature) under non-reducing (NR) condition (SDS-PAGE) due to glycosylation and Interchain disulfide bond.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial"
Gupta, Oh, Devos et al
Leuk Lymphoma (2024)
(2) "iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva"
Gao, Inada, Hotta et al
Stem Cell Res Ther (2024) 15 (1), 83
(3) "The prognostic value and potential immunotherapeutic efficacy of ACVR1 in treating gastric cancer"
Zhang, Liu, Chen et al
J Gastrointest Oncol (2024) 15 (1), 63-85
Showing 1-3 of 3676 papers.